We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
- Authors
Dispenzieri, A; Seenithamby, K; Lacy, M Q; Kumar, S K; Buadi, F K; Hayman, S R; Dingli, D; Litzow, M R; Gastineau, D A; Inwards, D J; Micallef, I N; Ansell, S M; Johnston, P B; Porrata, L F; Patnaik, M M; Hogan, W J; Gertz, M A A
- Abstract
The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of 'tumor burden' but also in terms of their underlying biology. High-dose chemotherapy with auto-SCT is one method of reducing the clone size and thereby improving OS. Post-auto-SCT outcomes between the two diseases have never been formally compared. Among all patients with a diagnosis of AL or MM who received auto-SCT as primary therapy at the Mayo Clinic, Rochester, there were higher CR rates (40% versus 29%, P<0.0001) in the AL group. The respective median OS for the AL and MM patients was 113 and 59.5 months, respectively, P<0.0001. Among patients achieving CR, MM patients had a fivefold risk of death as compared with AL patients. Although auto-SCT cannot be offered to all patients with either AL or MM, it appears that for those well enough to be chosen for the procedure, greater benefit is derived among the AL patients. This difference in survival is most notable among those patients who achieve CR, suggesting very different plasma cell biology between the two diseases.
- Subjects
IMMUNOGLOBULINS; AMYLOIDOSIS; PROTEIN metabolism disorders; B cell lymphoma; MULTIPLE myeloma
- Publication
Bone Marrow Transplantation, 2013, Vol 48, Issue 10, p1302
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/bmt.2013.53